华东医药：HDM1005注射液完成减重适应症中国Ⅲ期临床研究首例受试者随机给药

Core Viewpoint - East China Pharmaceutical announced that its wholly-owned subsidiary, Hangzhou Sino-American East China Pharmaceutical Co., Ltd., has completed the first random dosing of HDM1005 injection, a GLP-1/GIP dual-target long-acting agonist, in the Phase III clinical study for weight loss indication in China [1] Group 1 - The clinical study is identified as HDM1005-301 [1] - The drug is designed to target both GLP-1 and GIP pathways, which are significant in weight management [1] - The completion of the first random dosing marks a critical milestone in the development of HDM1005 [1]